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Poster Session II S333between the groups except a higher percentage of normal cytogenet-
ics in patients with FLT3/ITD+ (p 5 0.025).Two year OS, DFS,
non-relapse mortality (NRM), and relapse of cohort were 60.8%,
55.8%, 18.0% and 31.3%, respectively. Univariate analysis showed
FLT3/ITD+ compared to FLT3/ITD- patients was significantly as-
sociated with inferior DFS (2 year DFS: 19% vs. 64%, p\0.0027),
increased risk of relapse (1 year: 59%vs. 19%, p\0.0009), and a trend
towards decreased OS (p 5 0.08). 5 of the 16 FLT3/ITD+ patients
were also positive for NPM1, which did not impact outcome. Mul-
tivariate analysis using the Cox proportion hazard regression model
confirmed that FLT3/ITD+ mutations independently predicted
a shorter DFS (hazard ratio [HR], 3.0; 95% CI, 1.4-6.5; p 5
0.004) and increased risk of relapse (HR, 4.9; 95% CI, 2.0-12.3,
p 5 0.001). Time to relapse in patients with FLT3/ITD+ was very
short with 100 days cumulative risk of 45%.
Conclusion:Our data suggests that allo-SCT in FLT3/ITD+ AML
CR1 does not appear to overcome the poor prognostic value, and
these patients remain at high risk of early relapse even after allo-
SCT.While our study is limited by small size, this further illustrates
the urgent need for larger prospective studies to validate the efficacy
of allo-SCT in CR1 and the need to design therapy targeting FLT3/
ITD either prior to or early-post transplant to decrease relapse for
this specific subgroup.347
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Introduction: Fludarabine (F) and Busulfan (Bu) is a well-tolerated
conditioning regimen for allo HSCT. New nucleoside antimetabo-
lites are available with the potential for improved anti-tumor effect.
We substituted Clofarabine (Clo) for F for its better antileukemic ac-
tivity. To address the blood-brain barrier we added Thiotepa (Th),
a polyfunctional alkylating agent. These data report on combining
the Th + (IV)Bu + Clo in a conditioning regimen for high risk pa-
tients.
Patients and Methods: 31 patients received Th 5 mg/kg over 1 hr.
Bu was administered x 3 days over 3 hr to a daily AUC of 5,000
mcMol-min +/-10%. Clo 40mg/m2 was infused over 1 hr daily x 4
days. 29 patients are evaluable for engraftment and survival beyond
day + 30. M/F: 18/13. Median age 18 y (range 2-60). 16 patients
had AML [IF (2), relapse refractory (4), relapse untx(3), CR2 (6),
. CR2 (1)]. 14 patients had ALL [CR1 (1), CR2 (4), CR3 (5), Re-
lapse sensitive (2), relapse resistant (1) relapse untx(1)]. One patient
had CML ($ 3 CP). 7 had received prior transplants this being their
2nd (4), 3rd (2), 4th (1)]. GVHDprophylaxis was tacrolimus andmini-
MTX or tacrolimus and MMF (CB recipients). Those with one
Ag-mism or unrelated grafts received rabbit-ATG. Stem cell sources
included cord (17); MUD-apheresis (4), MUD-BM (5), MSD–
apheresis (4) MSD-BM (1).
Results: 15 patients are alive although 3 have relapsed (d132, d139,
d231) for a median OS 320 d (120-833). Common regimen-related
toxicities were GI and esophagitis. Self-limited hemorrhagic cystitis
due to BK virus occurred in 7 patients. Deaths from VOD/Pulmo-
nary hemorrhage (4) occurred in patients receiving Gemtuzumab
Ozogamicin or Inotuzumab ozogamicin therapy. Acute GVHD oc-
curred in  50% of all patients Grade II-IV (7). None (12) NE (4).
Chronic GVHD occurred in 5 patients, none (19), NE (7). Deaths
(16) were due to relapse (9) PFS 90 d (30-279), late infection (1)
d 259. The other 6 patients who died all received ozogamicin ther-
apy. PB microsatellite chimerism at day +30 showed 100% donor
T cell and myeloid cells in all but 4 patients who went on to relapse.
Conclusion: This regimen is overall safe unless administered after
recent ozogamicin therapy. Significantly, patients with refractory
disease at the time of HSCT achieved a CR. Engraftment in recipi-
ents of UCB transplants was robust (medium 18 days). In aggregate,
this chemotherapy regimen provided an anti-leukemia effect and
warrants further investigation.348
ADOPTIVE IMMUNOTHERAPY USING ANTI-THYMOCYTE GLOBULIN AND
REDUCED INTENSITY TOTAL BODY IRRADIATION; A COST-EFFECTIVE
STRATEGY FOR ALLOGENEIC STEM CELL TRANSPLANTATION
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Allogeneic stem cell transplants (SCT) conditioned with conven-
tional regimens continue to be fraughtwith complications, increasing
resource utilization and downstream costs associated with these
procedures. We have developed an investigational conditioning reg-
imen, incorporating anti-thymocyte globulin (ATG; Thymoglobu-
lin, Sanofi-Aventis) and reduced-intensity total body irradiation,
with the goal of reducing complications following SCT
(NCT00709592). To determine the cost savings associated with
the use of this regimen, we performed a retrospective analysis of di-
rect costs incurred during the first 100 days following SCT.We com-
pared the investigational group of patients (IG; n5 25) with a control
group transplantedduring the same timeperiodand conditionedwith
either reduced intensity busulfan ormelphalan + fludarabine contain-
ing regimens (CG; n5 32). The IG and CG differed in age (57 vs. 53
years; F-Test, p5 0.04), number of prior regimens (4 vs. 2; p\0.01),
and disease distribution (p\0.001), but had a similar proportion of
matched related and unrelated donors (p 5 0.12). At a median fol-
low-up of 20months in the IG and 12months in the CG, the survival
in the two groups is similar (one-year K-M survival estimate 73% vs.
53%, Log Rank p 5 0.16). Inpatient hospitalization following SCT
was shorter for IG, 17 (67) days, compared to the CG, 24 (616)
days (p 5 0.02). Direct cost incurred during the study period was
lower for the IG ($121,103 6 47,292) compared to the CG
($194,392 6 93,760) (p\0.01), this despite the entire IG surviving
to day 100 (4 deaths in the CG). When patients who relapsed or
died during this period were excluded from analysis the cost differ-
ence remained in favor of the IG, $118,546 6 48,567 vs. $188,239
6 92,484 for the CG (p\0.01). Table 1 displays the trends in the
cost incurred over time for the investigational and control groups.
The cost savings spanned a variety of categories, including pharma-
ceutical, blood bank, laboratory and inpatient charges. We conclude
that despite being heavily pretreated, patients conditioned with the
investigational ATG + TBI regimen spent fewer days in the hospital
and had a lower cost associated with transplantation. Given the cur-
rent economic climate, our findings suggest that rethinking conven-
tional methods of reduced-intensity conditioning, with emphasis on
adoptive immunotherapy rather than dose intensity,may improve the
cost-effectiveness of allogeneic SCT.
Table 1. Total and InpatientCostsUpToDay100FollowingSCT
Time Period Control Group Investigational Group p ValueTotal Costs
1-100 Days $194,392 $121,103 <0.01
1-30 Days $70,750 $49,306 <0.01
31-60 Days $30,216 $16,028 <0.01
61-100 Days $37,841 $16,709 0.05
Inpatient Costs
1-100 Days $51,442 $36,084 0.04
1-30 Days $26,266 $21,411 0.06
31-60 Days $7,732 $1,706 0.02
61-100 Days $11,972 $2,008 0.04The costs are mean values and standardized to FY 2012 $. The p-value
was calculated using analysis of variance (F test).
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ENCOURAGING SURVIVAL FOR PATIENTS WHO HAD A SECOND UMBILI-
CAL CORD BLOOD TRANSPLANT FOR GRAFT FAILURE
Lund, T.C.1, Verneris, M.R.1, Tolar, J.1, Cao, Q.2, Weisdorf, D.J.2,
Wagner, J.E.2, Brunstein, C.G.2 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
After umbilical cord blood transplantation (UCBT), the 10-15%
risk of graft failure (GF) remains a significant source or morbidity
